Drug intelligence / Profile preview

DS-1

Development stage: Unknown
Lead developer: Renji Hospital
Modality: Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Nebulized

Overview

DS-1 is a linear polyethylenimine-nitric oxide/nucleophile adduct, functioning as a water-soluble nitric oxide donor. Preclinically, it has demonstrated potent vasorelaxant properties and the ability to attenuate endotoxin-induced acute lung injury in sheep by reducing pulmonary hypertension and edema, and improving myocardial function and gas exchange. DS-1 is also undergoing clinical investigation in combination with cadonilimab for the treatment of localized advanced gastric cancer.

Targets

sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on DS-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DS-1.

Explore the full profile